Background: Histopathologic grading and clinical staging cannot provide a precise prognosis of oralcavitycancer patients.
2
Conclusions: The prognosis of oralcavitycancer has improved significantly from the early 1970s to recent years.
3
However, guidelines for the treatment of most forms of HNSCC do not exist in German-speaking countries with the exception of oralcavitycancer.
4
The objective of this study was to determine the efficacy of paclitaxel and PKI166, a novel inhibitor of EGFR, against oralcavitycancer.
5
We aimed to evaluate temporal trends in demographics, treatment, and prognosis of oralcavitycancer diagnosed between 1973 and 2014 inclusive.
6
There are limited data suggesting a change in prognosis of oralcavitycancers.
7
The incidence rates of potentially HPV-associated oropharyngeal and oralcavitycancers by various characteristics were estimated.
8
In particular, HPV is strongly associated with the development of oropharyngeal cancer and a small minority of oralcavitycancers.
9
Conclusions: NLR was first shown to be significantly elevated in oralcavitycancers and in oral cavity SCC in this study.
10
The current methodology described in this article should therefore afford pathologists original and quantitative (and thus objective) prognostic markers for oralcavitycancers.
11
Methods: This is a retrospective analysis of prospectively collected data of patients undergoing induction chemotherapy (IC) in oralcavitycancers from 2010 to 2012.